Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: the best of J.P. Morgan; Novartis on its US-first commercial plan; Chugai CEO talks to Scrip on the Roche alliance and more; Scrip Asks what this year holds for pricing and reimbursement; and the global outlook for biopharma funding.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 20 January 2023, including: the best of J.P. Morgan; Novartis AG on its US-first commercial plan; Chugai Pharmaceutical Co., Ltd. CEO talks to us on the Roche Holding AG alliance and more; Scrip Asks what this year holds for pricing and reimbursement; and the outlook for biopharma funding.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "The Best Of J.P. Morgan – Valuations, Deals And The IRA" - Scrip, 16 Jan, 2023.)
(Also see "Novartis On Its ‘US First’ Commercial Plan" - Scrip, 17 Jan, 2023.)
(Also see "Chugai Building On Roche Alliance Success As It Eyes Future: CEO Okuda" - Scrip, 16 Jan, 2023.)
(Also see "Scrip Asks… What Does 2023 Hold For Biopharma? Part 4: Pricing And Reimbursement" - Scrip, 18 Jan, 2023.)
(Also see "Biopharma Funding Contracted Last Year – And 2023 Will See The Squeeze Continue" - Scrip, 16 Jan, 2023.)